Antonius A Miller

Antonius A Miller

UNVERIFIED PROFILE

Are you Antonius A Miller?   Register this Author

Register author
Antonius A Miller

Antonius A Miller

Publications by authors named "Antonius A Miller"

Are you Antonius A Miller?   Register this Author

46Publications

760Reads

7Profile Views

Frailty assessment predicts toxicity during first cycle chemotherapy for advanced lung cancer regardless of chronologic age.

J Geriatr Oncol 2019 01 10;10(1):48-54. Epub 2018 Jul 10.

Department of Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2018.06.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785179PMC
January 2019

A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma.

PLoS One 2016 12;11(10):e0164244. Epub 2016 Oct 12.

Department of Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0164244PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061374PMC
May 2017

Phase II Trial of Angiotensin-(1-7) for the Treatment of Patients with Metastatic Sarcoma.

Sarcoma 2016 8;2016:4592768. Epub 2016 Nov 8.

Department of Medicine, Section of Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USA; Comprehensive Cancer Center of Wake Forest University, Wake Forest School of Medicine, Winston-Salem, NC, USA; Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2016/4592768DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118533PMC
November 2016

Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).

J Clin Oncol 2015 May 2;33(15):1660-5. Epub 2015 Mar 2.

Neal E. Ready and Jeffrey Crawford, Duke University Medical Center; Herbert H. Pang and Lin Gu, Alliance Statistics and Data Center, Duke University Medical Center, Durham; Antonius A. Miller, Wake Forest University Medical Center, Winston Salem, NC; Gregory A. Otterson, Ohio State University Medical Center, Columbus, OH; Sachdev P. Thomas, Illinois Oncology Research Association Community Clinical Oncology Program, Illinois Cancer Care, Peoria; Everett E. Vokes, University of Chicago, Chicago, IL; Maria Baggstrom, Washington University School of Medicine, St Louis, MO; Gregory A. Masters, Christiana Healthcare Services, Christiana Hospital, Newark, DE; Stephen L. Graziano and Jeffrey Bogart, State University of New York Upstate Medical University, Syracuse, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.3105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429175PMC
May 2015

Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer.

J Thorac Oncol 2014 Apr;9(4):572-6

*Department of Radiation Oncology, Wake Forest Baptist Health, Winston-Salem, North Carolina; and †Department of Hematology and Oncology, Wake Forest Baptist Health, Winston-Salem, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000086DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075996PMC
April 2014

The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).

Pharmacogenet Genomics 2013 Jan;23(1):29-33

Sections of Clinical Pharmacology and Hematology/Oncology, Department of Medicine, The Geisel School of Medicine at Dartmouth, The Norris Cotton Cancer Center, Lebanon, NH 03756, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0b013e32835b16d8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647228PMC
January 2013

Reverse translation of phase I biomarker findings links the activity of angiotensin-(1-7) to repression of hypoxia inducible factor-1α in vascular sarcomas.

BMC Cancer 2012 Sep 11;12:404. Epub 2012 Sep 11.

Department of Medicine, Section on Hematology and Oncology, Wake Forest University Health Sciences, Medical Center Boulevard, Winston-Salem, NC 27157, USA.

View Article

Download full-text PDF

Source
http://bmccancer.biomedcentral.com/articles/10.1186/1471-240
Publisher Site
http://dx.doi.org/10.1186/1471-2407-12-404DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495013PMC
September 2012

Effects of continued tobacco use during treatment of lung cancer.

Expert Rev Anticancer Ther 2010 Oct;10(10):1569-75

Department of Medicine, Section on Hematology and Oncology, Winston-Salem, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.10.140DOI Listing
October 2010

Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke.

Lung Cancer 2010 Jan;67(1):12-6

Department of Medicine, Section on Hematology and Oncology, Wake Forest University Health Sciences, Winston-Salem, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2009.08.014DOI Listing
January 2010

Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone.

Clin Cancer Res 2009 Dec 17;15(23):7398-404. Epub 2009 Nov 17.

Department of Medicine, Section on Hematology and Oncology, Wake Forest University Health Sciences, Winston-Salem, North Carolina 27157, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-1957DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3703919PMC
December 2009

Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results database.

Lung Cancer 2009 May 2;64(2):226-31. Epub 2008 Oct 2.

Wake Forest University Health Sciences, Department of Radiation Oncology, Medical Center Boulevard, Winston-Salem, NC 27157, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2008.08.010DOI Listing
May 2009

Small cell lung cancer: have we made any progress over the last 25 years?

Oncologist 2007 Sep;12(9):1096-104

Department of Radiation Oncology, Wake Forest University Health Sciences, Winston-Salem, North Carolina, USA.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.12-9-1096DOI Listing
September 2007

Phase I study of lenalidomide in solid tumors.

J Thorac Oncol 2007 May;2(5):445-9

Wake Forest University, Comprehensive Cancer Center, Winston-Salem, NC 27157, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.JTO.0000268679.33238.67DOI Listing
May 2007

A pharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced non-small cell lung cancer.

J Thorac Oncol 2007 Mar;2(3):197-202

Department of Medicine, Section on Hematology and Oncology, Wake Forest University Health Sciences, Winston-Salem, North Carolina 27157, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e318031cd89DOI Listing
March 2007

Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.

Lung Cancer 2006 Dec 16;54(3):379-85. Epub 2006 Oct 16.

Comprehensive Cancer Center of Wake Forest University, Section on Hematology and Oncology, Medical Center Boulevard, Winston-Salem, NC 27157, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2006.07.010DOI Listing
December 2006

Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer.

J Thorac Oncol 2006 Oct;1(8):832-6

Comprehensive Cancer Center, Wake Forest University, Winston-Salem, North Carolina, USA.

View Article

Download full-text PDF

Source
October 2006

Phase Ia/Ib chemo-radiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/B non-small cell lung cancer.

J Thorac Oncol 2006 Jun;1(5):434-40

Department of Radiation Oncology, Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina 27516, USA.

View Article

Download full-text PDF

Source
June 2006

Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study.

Cancer Chemother Pharmacol 2006 Jan 13;57(2):199-206. Epub 2005 Sep 13.

Department of Biopharmaceutical Sciences, The University of Illinois at Chicago, 833 South Wood Street (MC 865), Chicago, IL 60612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-005-0023-6DOI Listing
January 2006

Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004).

Lung Cancer 2005 Jun 23;48(3):399-407. Epub 2005 Jan 23.

Comprehensive Cancer Center of Wake Forest University, Medical Center Blvd., Winston-Salem, NC 27157, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2004.11.019DOI Listing
June 2005

Body surface area in dosing anticancer agents: scratch the surface!

J Natl Cancer Inst 2002 Dec;94(24):1822-3

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/94.24.1822DOI Listing
December 2002

Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study.

Lung Cancer 2002 Jul;37(1):1-6

Department of Medicine, Section of Pulmonary and Critical Care, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1054, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0169-5002(01)00492-5DOI Listing
July 2002